Rapid Decay of Anti–SARS-CoV-2 Antibodies in Persons with Mild Covid-19

F. Javier Ibarrondo; Jennifer A. Fulcher; David Goodman‐Meza; Julie Elliott; Christian Hofmann; Mary Ann Hausner; Kathie G. Ferbas; Nicole H. Tobin; Grace M. Aldrovandi; Otto O. Yang

doi:10.1056/nejmc2025179

July 21, 2020New England Journal of MedicineOpen Access

Rapid Decay of Anti–SARS-CoV-2 Antibodies in Persons with Mild Covid-19

View Full Paper

Ask AI

Bookmark

Share

Key Points

This research aims to investigate the duration of antiviral antibodies following mild COVID-19 infection.
Examined antibody levels in 34 volunteers who recovered from mild COVID-19 infection.
Measured antibodies to the receptor-binding domain of the SARS-CoV-2 spike protein over time.
Anti-SARS-CoV-2 antibodies significantly declined after recovery from mild COVID-19.
Most participants showed a rapid decrease in antibody levels, indicating potential short-lived immunity.

Ask about this paper

Answers are grounded in this paper and cite their sources.

Implication

Examines antibody decline in individuals with mild COVID-19, suggesting rapid immunity loss.

Abstract

Covid-19 Antibodies after Mild Infection Among 34 volunteers who had recovered from mild Covid-19 illness, antiviral antibodies to the receptor-binding domain of the viral spike protein declined wi...

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Ibarrondo et al. (2020) studied this question.

synapsesocial.com/papers/6a6a541934b735385cb37e36 https://doi.org/10.1056/nejmc2025179

View Full Paper

Ask AI

Bookmark

Share

Rapid Decay of Anti–SARS-CoV-2 Antibodies in Persons with Mild Covid-19

Key Points

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Rapid Decay of Anti–SARS-CoV-2 Antibodies in Persons with Mild Covid-19

Key Points

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading